Literature DB >> 10966567

Tyrosinase immunoreactivity in fine-needle aspiration samples of metastatic malignant melanoma.

P A Fetsch1, A I Riker, F M Marincola, A Abati.   

Abstract

BACKGROUND: Tyrosinase, the rate-limiting enzyme in melanin synthesis, is a melanoma associated antigen that is recognized by both CD4+ and CD8+ T-cells in an HLA-restricted fashion. Peptides derived from the tyrosinase antigen currently are being utilized as a target for T-cells in several immunotherapy protocols for metastatic malignant melanoma (MMM) at the National Institutes of Health/National Cancer Institute. Serial fine-needle aspirations of metastatic lesions are performed to monitor the antigen expression of tyrosinase during treatment by immunostaining cytologic preparations with the monoclonal antibody T311.
METHODS: In the current study, 62 samples of MMM were evaluated for tyrosinase immunoreactivity on air-dried, acetone fixed cytospins and the corresponding formalin fixed, paraffin embedded cell block using an avidin-biotin immunoperoxidase method.
RESULTS: Positive immunoreactivity revealed a granular cytoplasmic staining in melanocytic cells. The current study results showed that 92% of samples (57 of 62) were T311 immunoreactive on cell block preparations, whereas only 61% (38 of 62) were immunoreactive on cytospin preparations. In 66% of samples (41 of 62) immunoreactivity for T311 was greater in the cell block sample than in the corresponding cytospin, whereas in only 3% of samples (2 of 62) was it greater in the cytospins. In 31% of samples (19 of 62) there was no significant difference in immunoreactivity between the 2 sample types.
CONCLUSIONS: The results of the current study show that tyrosinase is a sensitive marker for the detection of MMM; however, the optimal method of sample preparation for immunoperoxidase staining appears to be formalin fixation and paraffin embedding as tyrosinase immunoreactivity is diminished significantly in air-dried cytospin samples despite subsequent acetone fixation. Cancer (Cancer Cytopathol) Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10966567     DOI: 10.1002/1097-0142(20000825)90:4<252::aid-cncr9>3.0.co;2-n

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.

Authors:  Kimberly R Lindsey; Linda Gritz; Richard Sherry; Andrea Abati; Patricia A Fetsch; Lisa C Goldfeder; Monica I Gonzales; Kimberly A Zinnack; Linda Rogers-Freezer; Leah Haworth; Sharon A Mavroukakis; Donald E White; Seth M Steinberg; Nicholas P Restifo; Dennis L Panicali; Steven A Rosenberg; Suzanne L Topalian
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration.

Authors:  Edmund K Bartlett; Udai S Kammula; Patricia A Fetsch; Armando C Filie; Andrea Abati; Seth M Steinberg; John R Wunderlich; Donald E White; Daniel J Stephens; Francesco M Marincola; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2014-03-19       Impact factor: 12.531

Review 3.  Cytologic diagnosis of metastatic melanoma by FNA: A practical review.

Authors:  Andrea Ronchi; Marco Montella; Federica Zito Marino; Giuseppe Argenziano; Elvira Moscarella; Gabriella Brancaccio; Giuseppe Ferraro; Giovanni Francesco Nicoletti; Teresa Troiani; Renato Franco; Immacolata Cozzolino
Journal:  Cancer Cytopathol       Date:  2021-07-26       Impact factor: 4.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.